An Executive Bought a Rival’s Stock. The SEC Says That’s Insider Trading.
Reported by Dave Michaels Biotech executive Matthew Panuwat bought options on another drug company’s stock—and earned a windfall of $120,000. The Securities and Exchange Commission now says he committed insider trading, even though he didn’t buy his employer’s stock and didn’t have inside information about the company he bet on. The case, which goes to […]